Drug intelligence / Profile preview

AM-831

Development stage: Discontinued
Lead developer: Acadia Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

AM-831 is an orally available small molecule antipsychotic drug candidate that combines muscarinic M1 partial agonism with both dopamine D2 and serotonin 5-HT2A antagonism. It was developed by ACADIA Pharmaceuticals in collaboration with Meiji Seika Pharma for the treatment of schizophrenia. Preclinical studies indicated that AM-831 had both antipsychotic and pro-cognitive effects. However, development was discontinued after Phase I clinical trials did not meet predetermined criteria for further advancement.

Targets

M1 (Muscarinic acetylcholine receptor M1)HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on AM-831.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM-831.

Explore the full profile